BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
BridgeBio reported Q1 total revenue of $194.5 million, up 67% year-over-year, driven by $180.6 million in U.S. Attruby net product revenue. The company submitted an NDA for BBP-418 for LGMD2I/R9, with plans to submit NDAs for encaleret in 1H 2026 and oral infigratinib in Q3 2026.
Key figures
- Revenue
- 194515000
- Drug Name
- Attruby (acoramidis)
- Guidance
- BBP-418 NDA submitted; Encaleret NDA expected 1H 2026; Infigratinib NDA expected Q3 2026.
- Revenue Yoy
- 66.8%
- Rd expenses
- 126636000
- Sga expenses
- 163896000
- Royalty revenue
- 9500000
- Operating expenses
- 300471000
- Net product revenue
- 180596000
- Buyback authorization
- 500000000
- License and services revenue
- 4419000
- Cash and marketable securities
- 940200000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.